Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0001104659-25-076281·BIOS Fund III, LP
Schedule 13G ownership disclosure
REIN THERAPEUTICS INC
Common Stock, $0.0001 par value per share · CUSIP: 00887A204
Event date: 2025-05-05
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- BIOS FUND III, LP
Shares: 430,665.00 · Class: 0.7%
- BIOS FUND III QP, LP
Shares: 2,801,953.00 · Class: 4.7%
- BIOS FUND III NT, LP
Shares: 450,811.00 · Class: 0.8%
- BIOS EQUITY PARTNERS III, LP
Shares: 3,683,429.00 · Class: 6.2%
- CAVU MANAGEMENT, LP
Shares: 3,683,429.00 · Class: 6.2%
- BIOS CAPITAL MANAGEMENT, LP
Shares: 3,683,429.00 · Class: 6.2%
- CAVU ADVISORS, LLC
Shares: 3,683,429.00 · Class: 6.2%
- BIOS ADVISORS GP, LLC
Shares: 3,683,429.00 · Class: 6.2%
- LESLIE WAYNE KREIS, JR.
Shares: 3,683,429.00 · Class: 6.2%
- AARON GLENN LOUIS FLETCHER
Shares: 3,683,429.00 · Class: 6.2%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-25-076281
- Form type
- SCHEDULE 13G
- Filer
- BIOS Fund III, LP
- CIK
- CIK 1791917
- Filed
- Aug 11, 2025
- Reporting period
- May 05, 2025
- Description
- Schedule 13G beneficial ownership